ArticleBiomaterials2014
Combined use of chondroitinase-ABC, TGF-β1, and collagen crosslinking agent lysyl oxidase to engineer functional neotissues for fibrocartilage repair.
Article in Biomaterials, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- Bioassembly of Region-Specific Fibrocartilage Microtissues to Engineer Zonally Defined Meniscal Grafts.Advanced healthcare materials · 2025Article
- A multifunctional scaffold that promotes the scaffold-tissue interface integration and rescues the ROS microenvironment for repair of annulus fibrosus defects.Bioactive materials · 2024Article
- A cell bank paradigm for preclinical evaluation of an analogous cellular product for an allogeneic cell therapy.Biofabrication · 2024Article
- Temporal Enzymatic Treatment to Enhance the Remodeling of Multiple Cartilage Microtissues into a Structurally Organized Tissue.Advanced healthcare materials · 2024Article
- Chondroitinase ABC Treatment Improves the Organization and Mechanics of 3D Bioprinted Meniscal Tissue.ACS biomaterials science & engineering · 2023Article
- Temporal application of lysyl oxidase during hierarchical collagen fiber formation differentially effects tissue mechanics.Acta biomaterialia · 2023Article
- Review
- Ion modulatory treatments toward functional self-assembled neocartilage.Acta biomaterialia · 2022Article
- Non-destructive, continuous monitoring of biochemical, mechanical, and structural maturation in engineered tissue.Scientific reports · 2022Article
- Intracellular Calcium and Sodium Modulation of Self-Assembled Neocartilage Using Costal Chondrocytes.Tissue engineering. Part A · 2022Article
- The Effect of Neonatal, Juvenile, and Adult Donors on Rejuvenated Neocartilage Functional Properties.Tissue engineering. Part A · 2022Article
- Inductive Remodeling of Extracellular Matrix Scaffolds in the Temporomandibular Joint of Pigs.Tissue engineering. Part A · 2022Article
- The functionality and translatability of neocartilage constructs are improved with the combination of fluid-induced shear stress and bioactive factors.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022Article
- Tissue Engineering of Canine Cartilage from Surgically Debrided Osteochondritis Dissecans Fragments.Annals of biomedical engineering · 2022Article
- Article
- Rejuvenation of extensively passaged human chondrocytes to engineer functional articular cartilage.Biofabrication · 2021Article
- Shear stress induced by fluid flow produces improvements in tissue-engineered cartilage.Biofabrication · 2020Article
- Engineering self-assembled neomenisci through combination of matrix augmentation and directional remodeling.Acta biomaterialia · 2020Article
- Surgical and tissue engineering strategies for articular cartilage and meniscus repair.Nature reviews. Rheumatology · 2019Review
- Remaining Hurdles for Tissue-Engineering the Temporomandibular Joint Disc.Trends in molecular medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Patients suffering from damaged or diseased fibrocartilages currently have no effective long-term treatment options. Despite their potential, engineered tissues suffer from inferior biomechanical integrity and an inability to integrate in vivo. The present study identifies a treatment regimen (including the biophysical agent chondroitinase-ABC, the biochemical agent TGF-β1, and the collagen crosslinking agent lysyl oxidase) to prime highly cellularized, scaffold-free neofibrocartilage implants, effecting continued improvement in vivo. We show these agents drive in vitro neofibrocartilage matrix maturation toward synergistically enhanced Young's modulus and ultimate tensile strength values, which were increased 245% and 186%, respectively, over controls. Furthermore, an in vitro fibrocartilage defect model found this treatment regimen to significantly increase the integration tensile properties between treated neofibrocartilage and native tissue. Through translating this technology to an in vivo fibrocartilage defect model, our results indicate, for the first time, that a pre-treatment can prime neofibrocartilage for significantly enhanced integration potential in vivo, with interfacial tensile stiffness and strength increasing by 730% and 745%, respectively, compared to integration values achieved in vitro. Our results suggest that specifically targeting collagen assembly and organization is a powerful means to augment overall neotissue mechanics and integration potential toward improved clinical feasibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.